hydrochlorothiazide has been researched along with cardiovascular agents in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (16.67) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hancock, EW | 1 |
| Kaplan, HR; Smith, RD; Tessman, DK | 1 |
| Cornell, ES; Heckbert, SR; Psaty, BM; Smith, NL; Tracy, RP | 1 |
| Johnston, GA | 1 |
| SCHULTZ, FB | 1 |
| Lechat, P; Médiani, O; Mougenot, N | 1 |
| Al Ajrawi, T; Al Said, AN; Römpler, H; Sangkuhl, K; Schöneberg, T; Zaki, M | 1 |
| Bailey, MA; Hasenfuss, G; Knauf, H; Mutschler, E | 1 |
| Kumar, V; Shah, RP; Singh, S | 1 |
| Forslund, L | 1 |
| Afzal, R; Pais, P; Pogue, J; Sigamani, A; Xavier, D; Yusuf, S | 1 |
| Dissanayake, WP; Furberg, CD; Gunaratne, PS; Jayasingne, IK; Mendis, S; Soliman, EZ; Somasundaram, NP | 1 |
| Cheng, KK; Etemadi, A; Hemming, K; Jaafari, E; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marjani, H; Marshall, T; Merat, S; Mohammadifard, N; Naemi, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Sadeghi, M; Sarrafzadegan, N; Thomas, GN | 1 |
| Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Visseren, FLj; Webster, R | 1 |
| Luteijn, JM; Morris, JK; Oppenheimer, P; Taylor, D; Wald, NJ | 1 |
| Luteijn, JM; Morris, JK; Wald, NJ | 1 |
| Absalan, G; Ahmadi, R; Ramezani, AM | 1 |
| Boffetta, P; Brennan, P; Cheng, KK; Etemadi, A; Fazel, A; Gharavi, A; Hemming, K; Kamangar, F; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marshall, T; Merat, S; Mohammadifard, N; Naemi-Tabiei, M; Nalini, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Roshandel, G; Sadeghi, M; Sarrafzadegan, N; Thomas, N | 1 |
6 trial(s) available for hydrochlorothiazide and cardiovascular agents
| Article | Year |
|---|---|
The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Agents; Cross-Over Studies; Cyclooxygenase Inhibitors; Diuretics; Drug Interactions; Drug Therapy, Combination; Electrolytes; Feedback, Physiological; Female; Glomerular Filtration Rate; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Natriuresis; Potassium | 2006 |
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atenolol; Capsules; Cardiovascular Agents; Cardiovascular Diseases; Diuretics; Double-Blind Method; Drug Combinations; Drug Costs; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Research Design; Secondary Prevention; Simvastatin; Treatment Outcome | 2009 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Chi-Square Distribution; Cholesterol; Diuretics; Drug Combinations; Feasibility Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Primary Prevention; Risk Assessment; Risk Factors; Simvastatin; Sri Lanka; Surveys and Questionnaires; Time Factors; Treatment Outcome; World Health Organization | 2011 |
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Protocols; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Polypharmacy; Primary Prevention; Research Design; Secondary Prevention; Sodium Chloride Symporter Inhibitors; Time Factors; Treatment Outcome; Valsartan | 2015 |
Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Cardiovascular Diseases; Diuretics; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Global Health; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Male; Medication Adherence; Middle Aged; Morbidity; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2016 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Valsartan | 2019 |
12 other study(ies) available for hydrochlorothiazide and cardiovascular agents
| Article | Year |
|---|---|
Bigeminal rhythm on multiple cardiac drug therapy.
Topics: Arrhythmias, Cardiac; Cardiovascular Agents; Digoxin; Drug Therapy, Combination; Electrocardiography; Furosemide; Humans; Hydrochlorothiazide; Male; Methyldopa; Middle Aged; Nitroglycerin; Potassium Chloride; Quinidine | 1984 |
Acute tolerance to prazosin in conscious hypertensive rats: involvement of the renin-angiotensin system.
Topics: Angiotensin II; Animals; Captopril; Cardiovascular Agents; Clonidine; Dose-Response Relationship, Drug; Drug Tolerance; Hydrochlorothiazide; Hypertension; Indomethacin; Male; Methyltyrosines; Prazosin; Propranolol; Quinazolines; Rats; Renin | 1981 |
The reliability of medication inventory methods compared to serum levels of cardiovascular drugs in the elderly.
Topics: Aged; Aspirin; Cardiovascular Agents; Digoxin; Humans; Hydrochlorothiazide; Patient Compliance; Propranolol; Reproducibility of Results | 1999 |
Thiazide-induced lichenoid photosensitivity.
Topics: Aged; Cardiac Output, Low; Cardiovascular Agents; Dermatitis, Photoallergic; Drug Combinations; Drug Eruptions; Humans; Hydrochlorothiazide; Lichenoid Eruptions; Male; Triamterene | 2002 |
The evaluation of hypertensive drugs.
Topics: Cardiovascular Agents; Hydrochlorothiazide; Hypertension; Reserpine | 1962 |
Bisoprolol and hydrochlorothiazide effects on cardiovascular remodeling in spontaneously hypertensive rats.
Topics: Animals; Bisoprolol; Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Heart Rate; Hydrochlorothiazide; Hypertension; Male; Rats; Rats, Inbred SHR; Ventricular Remodeling | 2005 |
Nephrogenic diabetes insipidus, thiazide treatment and renal cell carcinoma.
Topics: Amino Acid Sequence; Aquaporin 2; Carcinoma, Renal Cell; Cardiovascular Agents; Diabetes Insipidus, Nephrogenic; Female; Humans; Hydrochlorothiazide; Indomethacin; Infant, Newborn; Kidney Neoplasms; Male; Molecular Sequence Data; Sequence Homology, Amino Acid; Sodium Chloride Symporter Inhibitors | 2006 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
Reflections on the regulation of the Polypill.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Approval; Drug Combinations; Europe; Folic Acid; Government Regulation; Health Policy; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Practice Guidelines as Topic; Risk Assessment; Treatment Outcome | 2009 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort Studies; Cost-Benefit Analysis; Humans; Hydrochlorothiazide; Losartan; Markov Chains; Middle Aged; Myocardial Infarction; Polypharmacy; Primary Prevention; Quality-Adjusted Life Years; Simvastatin; Stroke; United Kingdom | 2016 |
Starting the polypill: the use of a single age cut-off in males and females.
Topics: Adult; Age Factors; Aged; Cardiovascular Agents; Drug Combinations; Female; Humans; Hydrochlorothiazide; Losartan; Male; Middle Aged; Myocardial Infarction; Preventive Health Services; Simvastatin; State Medicine; Stroke; United Kingdom | 2017 |
Green-modified micellar liquid chromatography for isocratic isolation of some cardiovascular drugs with different polarities through experimental design approach.
Topics: Cardiovascular Agents; Chromatography, High Pressure Liquid; Humans; Hydrochlorothiazide; Hydrophobic and Hydrophilic Interactions; Losartan; Micelles; Research Design; Software; Triamterene; United States; United States Food and Drug Administration | 2018 |